The FDA has approved Juvmo (tavapadon), AbbVie’s once-daily pill for Parkinson’s disease, on September 25, 2026. It is approved to improve motor function in adults with Parkinson’s and is the first drug of its kind: a selective partial agonist of the D1 and D5 dopamine receptors. That may sound technical, but it reflects a deliberate attempt to fix one of the oldest problems in Parkinson’s treatment.
The problem Juvmo is trying to solve
Parkinson’s disease destroys the brain cells that make dopamine, a chemical messenger needed for smooth, controlled movement. The result is slowness, stiffness and tremor. For decades, the backbone of treatment has been levodopa, which the brain converts into dopamine, and a class of drugs called dopamine agonists, which mimic dopamine directly.
Both have well-known drawbacks. Over years, levodopa’s effect tends to wear off between doses, producing “off” periods when symptoms return, and many people develop involuntary movements called dyskinesias. Older dopamine agonists such as pramipexole and ropinirole mainly act on the D2 and D3 receptors, and are linked to daytime sleepiness, hallucinations, swelling and impulse-control problems such as compulsive gambling or shopping. Those side effects often limit how much of the drugs people can take.
How tavapadon is different
Dopamine acts on several receptor types. The D1 and D5 receptors are closely involved in the brain circuits that drive movement. Tavapadon is designed to stimulate those receptors selectively, and only partially, rather than switching them fully on. The idea is to restore motor control while avoiding the D2/D3 activity associated with many of the troublesome side effects of older agonists, and to provide a steadier effect than levodopa’s peaks and troughs. Its long half-life allows once-daily dosing.
The evidence
The approval rests on the Phase 3 TEMPO program. In TEMPO-1 and TEMPO-2, which tested tavapadon on its own in people with earlier Parkinson’s, using fixed and flexible doses, it significantly improved motor symptoms compared with placebo. In TEMPO-3, in people already taking levodopa who had motor fluctuations, adding tavapadon significantly reduced those fluctuations compared with levodopa alone, increasing the time people spent with good symptom control. That combination of results supports use both as a first treatment and as an add-on later in the disease.
Why side effects matter so much in Parkinson’s
Parkinson’s is a long illness, often lasting decades, and most people take dopamine-acting drugs for many years. That makes tolerability as important as effectiveness. Impulse-control disorders are a clear example: large studies have found that roughly one in six people taking conventional dopamine agonists develop problems such as compulsive gambling, shopping, eating or hypersexuality, which can damage finances and relationships and are often hidden out of embarrassment. Sudden sleepiness can make driving dangerous, and hallucinations become more common with age. Many people end up on lower doses than would best control their movement, or stop agonists altogether. A drug that delivers motor benefit with fewer of these problems would matter a great deal — which is the bet behind tavapadon’s design, and what longer real-world experience will need to confirm.
Where it fits
For someone newly diagnosed, doctors often face a choice between starting levodopa or a dopamine agonist. Juvmo offers a new option in that decision, potentially with fewer of the side effects that make agonists difficult, although head-to-head comparisons with existing drugs are still needed to show how large that advantage is in practice. For people further along who are experiencing “off” periods on levodopa, it adds another once-daily add-on to a toolkit that includes MAO-B inhibitors, COMT inhibitors and other agents.
The business story
Tavapadon came to AbbVie through its $8.7 billion acquisition of Cerevel Therapeutics in 2024. The approval strengthens AbbVie’s Parkinson’s franchise alongside Vyalev, its continuous under-the-skin infusion of levodopa-based therapy for advanced disease. Analysts at William Blair have described the two as meaningful growth drivers. With Parkinson’s cases rising as populations age, the market for better-tolerated treatments is large.
What Juvmo doesn’t do
Like every approved Parkinson’s drug, Juvmo treats symptoms; it has not been shown to slow the underlying loss of brain cells. No drug has yet been proven to modify the course of Parkinson’s, although several experimental approaches, from alpha-synuclein antibodies to cell therapies, are in trials. Side effects still occur, and anyone starting it will need monitoring and dose adjustment, as with other dopamine-acting drugs.
What it means for patients
For the roughly one million Americans living with Parkinson’s, Juvmo is a genuinely new option rather than another version of an old one. Its real-world value will depend on how it compares with established treatments in everyday practice, how well people tolerate it over years, and what it costs; AbbVie had not detailed pricing at approval. Patients interested in it should discuss with their neurologist whether it fits their stage of disease and current treatment. This is regulatory news, not medical advice.